Crossmark

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s13014-021-01979-z

Published Online: 2022-01-15

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mayahara, Hiroshi http://orcid.org/0000-0001-6378-4437
Uehara, Kazuyuki

Harada, Aya

Kitatani, Keiji

Yabuuchi, Tomonori

Miyazaki, Shuichirou

Ishihara, Takeaki

Kawaguchi, Hiroki

Kubota, Hikaru

Okada, Hideaki

Ninomaru, Taira

Shindo, Chihiro

Hata, Akito
License Information

Text and Data Mining valid from 2022-01-15

Version of Record valid from 2022-01-15
More Information

Article History

Received: 24 August 2021

Accepted: 28 December 2021

First Online: 15 January 2022

Declarations

:

: The study protocol was approved by the Research Ethics Committee of our institution (reference number: 2020-[study05]-03). All study participants provided informed written consent for therapy. Because of the retrospective nature of this study, individual consent for study inclusion was exempted.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below